Background Midface toddler excoriation syndrome (MiTES) is a condition recently reported in three unrelated children. Habitual scratching from the first year of life inflicted deep, chronic, scarring wounds around the nose and eyes. One child had a mild neurological deficit but there was no other evidence of insensitivity to pain. Bilateral distribution and localization to the midface distinguish MiTES from other causes of self-inflicted skin damage such as trigeminal trophic syndrome. An earlier study of five siblings from a consanguineous Irish family, with lesions corresponding to MiTES plus other sensory deficits, showed homozygous mutations in a gene for hereditary sensory and autonomic neuropathy type VIII (HSAN8), PRDM12. Objectives To study further cases of MiTES, including analysis of PRDM12. Methods We describe five further children, from four families, with facial lesions typical of MiTES, in whom mutation analysis of PRDM12 was carried out. Results Homozygous or compound heterozygous pathogenic expansions of the PRDM12 polyalanine tract were found in four of five affected individuals, in three families. Conclusions Our finding of autosomal recessive mutations in PRDM12 in four of five patients with MiTES extends the phenotypic spectrum of PRDM12 mutations, which usually cause HSAN8, characterized by mutilating self-inflicted wounds of the extremities, lips and tongue. By contrast, MiTES shows severe midfacial lesions with little if any evidence of generalized pain insensitivity. The condition is probably genetically heterogeneous, and other congenital insensitivity to pain and HSAN genes such as SCN11A may be implicated. This new understanding of the nature of MiTES, which can masquerade as factitious disease, will facilitate appropriate management.
Summary
Background Midface toddler excoriation syndrome (MiTES) is a condition recently reported in three unrelated children. Habitual scratching from the first year of life inflicted deep, chronic, scarring wounds around the nose and eyes. One child had a mild neurological deficit but there was no other evidence of insensitivity to pain. Bilateral distribution and localization to the midface distinguish MiTES from other causes of self-inflicted skin damage such as trigeminal trophic syndrome. An earlier study of five siblings from a consanguineous Irish family, with lesions corresponding to MiTES plus other sensory deficits, showed homozygous mutations in a gene for hereditary sensory and autonomic neuropathy type VIII (HSAN8), PRDM12. Objectives To study further cases of MiTES, including analysis of PRDM12. Methods We describe five further children, from four families, with facial lesions typical of MiTES, in whom mutation analysis of PRDM12 was carried out. Results Homozygous or compound heterozygous pathogenic expansions of the PRDM12 polyalanine tract were found in four of five affected individuals, in three families. Conclusions Our finding of autosomal recessive mutations in PRDM12 in four of five patients with MiTES extends the phenotypic spectrum of PRDM12 mutations, which usually cause HSAN8, characterized by mutilating self-inflicted wounds of the extremities, lips and tongue. By contrast, MiTES shows severe midfacial lesions with little if any evidence of generalized pain insensitivity. The condition is probably genetically heterogeneous, and other congenital insensitivity to pain and HSAN genes such as SCN11A may be implicated. This new understanding of the nature of MiTES, which can masquerade as factitious disease, will facilitate appropriate management.
What's already known about this topic?
• Midface toddler excoriation syndrome (MiTES) is a newly recognized condition, described in three children, characterized by severe, chronic, scarring, self-inflicted midface excoriations, commencing in infancy.
• MiTES resembles fabricated and induced illness.
• The gene PRDM12 is responsible for an autosomal recessive disorder, hereditary sensory and autonomic neuropathy type VIII (HSAN8), characterized by congenital insensitivity to pain with ulceration to the extremities.
• A family with mild manifestations of HSAN8 and MiTES lesions had homozygous mutations in PRDM12.
What does this study add?
• We report a further five children with MiTES, in four families.
• Mutation analysis revealed biallelic mutations in PRDM12 in four children in three families. No mutations were found in the fifth child.
• This confirms MiTES as a recessive disorder of pain sensation, which is probably genetically heterogeneous.
• This new finding will improve our understanding of children presenting with this condition.
In 2017, three unrelated children were described with recurrent skin breakdown and scarring around the nose and eyes, present from the first year of life. 1 All were of South Asian origin, two from India and one from Pakistan. Clinical observation supported the parents' assertions that the children inflicted these wounds themselves by repeated scratching, apparently in response to itch. There was no evidence of any underlying infective or inflammatory condition and the children were otherwise healthy apart from mild developmental delay in one case. There was no other evidence of congenital insensitivity to pain (CIP) or hereditary autonomic sensory neuropathy (HSAN). The disorder was designated midface toddler excoriation syndrome (MiTES), a name chosen to reflect the anatomical distribution and age at onset of this condition. In addition to these three cases reported as MiTES, children with similar lesions of unknown cause have occasionally been discussed within the British Society for Paediatric Dermatology and reported in the literature, including a nonconsanguineous Irish family with five affected siblings. 2 Four of them had hypoaesthesia and three had abnormal nerve conduction studies. All five siblings were homozygous for a pathogenic 18-alanine repeat mutation in the terminal exon of the CIP gene PRDM12. 3 We report five further cases of MiTES in whom DNA was available for investigation of PRDM12, and review other similar cases reported in the literature.
Patients and methods

Clinical cases
Four of the children reported here (cases 1-4) presented to the dermatology department at the Indira Ghandi Institute of Child Health, Bangalore, India. Case 5 presented to Our Lady's Children's Hospital, Dublin. Clinical details of all cases reported to date are listed in Table 1 .
PRDM12 mutation detection
Genomic DNA was isolated from three families with MiTES, and targeted Sanger sequencing of all five PRDM12 exons was carried out. Sequencing primers were designed based on the mRNA sequence (NCBI reference: NM_021619.2). Polymerase chain reaction conditions and primer sequences are available on request. In case 5, DNA was analysed by a commercial laboratory.
Amplicons were purified by ExoSAP treatment (New England BioLabs, Ipswich, MA, U.S.A.), followed by generation of sequencing products using the BigDye Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, U.S.A.). Sequencing products were then cleaned up by ethanol precipitation and analysed on an ABI PRISM 3730 DNA Analyzer (Applied Biosystems). Where homozygous expansions of the exon 5 polyalanine tract were found in an affected child, the parents were also screened to determine whether the expansions were inherited or a result of de novo mutation.
For further investigation of family A we designed primers to sequence three dinucleotide repeats in the PRDM12 region; one proved to be polymorphic. This region of genomic DNA lies in intron 3 of PRDM12, and has a reference number of 22 CA repeats in the human genome (hg19, chr9:133,546,762-133,546,805).
Molecular analysis of PRDM12 in case 5 was undertaken by a commercial laboratory (CeGaT GmbH, T€ ubingen, Germany). Variants identified by next-generation sequencing were confirmed by Sanger sequencing.
Results
The clinical and molecular findings are summarized below and in Table 1 . Cases 1-3 were presented previously as a poster. 4 
Patient 1
This 4-year-old boy presented with skin lesions on the face from 9 months of age. He was born at term of related Indian parents and was otherwise healthy, with no relevant medical history. His parents reported that he scratched the lesions repeatedly. They had not observed blisters or photosensitivity. Both an older and younger sister had similar lesions.
Skin examination revealed lesions confined to the face (Fig. 1a ). There were postinflammatory hyperpigmented macules and atrophic scars with fresh excoriations on the forehead, nose, medial aspect of the eyes, perinasal and perioral region and chin. He was seen on three occasions over 10 months with lesions in various stages of healing, breakdown and scarring. Physical examination was otherwise normal.
Routine blood tests showed iron-deficiency anaemia with thrombocytosis and lymphocytosis. Serum uric acid and nerve conduction studies were normal. Biopsy of a healed area showed acanthosis, hyperkeratosis and increased dermal collagenization with a sparse lymphocytic infiltrate.
Molecular analysis in patient 1 and his affected sibling (patient 2) showed homozygous expansion of the PRDM12 polyalanine tract to 18 alanine residues. The mother was heterozygous for the expansion mutation and for a wild-type allele with 13 alanine residues, as expected for the carrier of a recessive phenotype. The father of siblings 1 and 2 was unexpectedly homozygous for seven alanine residues -this is the lowest reported number of alanines in the PRDM12 C-terminal expansion, and present in only 4% of alleles. Analysis of the CA22 repeat in intron 3 of PRDM12 showed normal segregation; he had two alleles (20/22), his wife had two alleles (21/22) and their affected children both also had two alleles (21/22). From this we concluded that the most likely explanation of his result was that he was heterozygous for a partial gene deletion of PRDM12 involving at least exon 5, and heterozygous for a seven-alanine repeat in exon 5. That is, he was hemizygous for the seven-alanine expansion, he had passed his exon 5 deletion to each of his affected children, and their haplotype was an 18-alanine expansion and exon 5 deletion. It proved impossible to confirm the presence (and extent) of the deletion by either single-nucleotide polymorphism chip analysis or multiplex ligation-dependent probe amplification, due to the very high GC content of PRDM12 exon 5.
Patient 2
The 1-year-old sister of case 1 had similar, although less extensive, lesions on the face from 4 months of age (Fig. 1b) . Her history was otherwise the same as for her brother. She too was otherwise healthy with no findings on physical examination apart from the facial lesions and an ill-defined erythematous plaque behind one ear. Again, blood tests showed iron-deficiency anaemia and thrombocytosis, with normal serum uric acid levels. Skin histology of an excoriated area was consistent with lichen simplex chronicus. The molecular findings are as for patient 1.
The 18-year-old sister of cases 1 and 2 was unavailable for examination but was reported to have had similar lesions from 3 months of age. They had settled with scarring but she still complained of itching.
Patient 3
This 2-year-old boy was the first of apparently monozygotic twins, and second child to related Indian parents. His skin lesions, confined to the face, appeared at 1 year of age and were similar to those described above (Fig. 1c) . He was otherwise healthy and developing normally. His cousin aged 23 years had reportedly experienced similar lesions in childhood leaving scars on the nose. Molecular testing showed the same homozygous expansion of the PRDM12 polyalanine tract to 18 alanine residues as found in cases 1 and 2. Both parents were heterozygous for the expansion mutation, and for a wild-type allele with 13 alanine residues, consistent with autosomal recessive inheritance.
Patient 4
This 3-year-old boy with third-degree-related Indian parents presented with similar skin lesions and global developmental delay. His parents reported constant nose scratching and picking from 1 year of age and the lesions had worsened considerably in the past 3 months. There was no family history of similar problems and no photosensitivity, and he was otherwise well. The skin lesions, as illustrated in Figure 1 (d), were confined to the face, and he was observed incessantly rubbing and slapping the affected area (Video S1; see Supporting Information). Investigations showed anaemia and thrombocytosis.
Nerve conduction studies in the facial nerves and both motor and sensory nerves of all four limbs were normal, as were serum uric acid and antinuclear antibodies. The child was treated with risperidone for 12 months with limited improvement. No mutations were found in any exon of PRDM12.
Patient 5
A 3-year-old boy, born to unrelated Irish parents, developed facial lesions from the age of 12 months. His parents reported persistent picking and scratching of the central face without any obvious pain or distress. He was also noted to have itchy eyes and chronic drooling of saliva. Developmental milestones were delayed. On examination he had deep excoriations at various stages of healing, extending from the right medial canthus along the nasal side wall and right cheek (Fig. 1e) . Magnetic resonance imaging of the brain was unremarkable and nerve conduction studies and electromyography were normal, but blink reflexes were equivocal. The picking is ongoing but has significantly lessened. Molecular analysis showed heterozygous expansion of the PRDM12 polyalanine tract to 18/17 alanine residues. 
Discussion
The PRDM12 gene, located at 9q34, encodes a transcriptional regulator and is key to the normal development of sensory neurons destined to become nociceptors. Biallelic mutations cause a congenital pain insensitivity disorder, HSAN type VIII, manifesting as ulceration to distal appendages, particularly the fingers, lips and tongue, as well as facial scratching. Largefibre sensory modalities (light touch, vibration and proprioception) are mostly normal, sweating and tearing are reduced, and autonomic dysfunction and the senses of smell and hearing are normal. The polyalanine tract in the final exon of PRDM12 is polymorphic, but the tract length in healthy individuals does not exceed 14 alanine residues. Homozygous expansion of the tract up to 18 or 19 alanine residues has been shown to be pathogenic in patients with congenital insensitivity to pain, and to cause intracellular PRDM12 protein aggregation. 3 The clinical features of these five patients (Table 1 , cases 1-5) closely resemble those of the three patients in our original report 1 (Table 1 , cases 6-8). The phenotype, reviewed in the light of these new cases, is as follows. (i) Onset is between 6 and 12 months of age; (ii) the sides of the nasal bridge seem to be sites of predilection; (iii) midfacial lesions predominate but there may be outlying facial lesions, for example on the chin and behind the ear; (iv) affected children are otherwise healthy apart from a tendency, at least in those from India, to iron-deficiency anaemia; (v) usually no abnormalities are detected on neurological examination and nerve conduction studies, but occasionally there is developmental delay and overt insensitivity to pain; and (vi) the condition appears to be inherited as an autosomal recessive trait.
Other patients with the same facial phenotype have occasionally been reported in the literature. Watson 2 reported a family of five affected Irish siblings, including identical twin girls, with 'facial picking' and abnormal pain sensation. They were included in a study of a new CIP gene PRDM12, along with other cases of autosomal recessive or isolated unexplained CIP or HSAN. 3 In 11 families including Watson's (family J), mutations were found in PRDM12. 3 The phenotype in family J was considerably milder than in the other patients in that series, being limited to facial scratching and rubbing, which settled after the first decade of life, and to diabetes-like foot ulcers. Only one other family in that series, a consanguineous family from Pakistan (family A), had a homozygous polyalanine tract expansion (19 alanine residues). The five affected individuals in family A were aged 11-39 years and had marked features of pain insensitivity including lip and finger biting; there is no specific mention of midfacial lesions, but lesions present in early childhood might have resolved. It may be that MiTES represents an early manifestation of HSAN, and that affected children will later develop the more typical acral and oral mutilating lesions. However, there was no suggestion of that from anecdotal reports of older affected individuals in the families we have studied.
A further family, a father and two children, was presented at the Royal Academy of Medicine in Ireland Dermatology Meeting, 5 December 2014. 2 They had a similar pattern of midfacial picking from infancy, improving with age. In addition, they had absent tendon reflexes and the father had Charcot joints. All three affected individuals had a missense mutation in a different CIP gene, SCN11A, which encodes a voltage-gated sodium channel mediating nociception; mutations cause familial episodic pain syndrome 3 and HSAN type VII, with pain insensitivity sometimes associated with delayed motor development. 5, 6 SCN11A is highly expressed in both trigeminal ganglia and dorsal root ganglia, consistent with localization of lesions to the face. This suggests that MiTES is genetically heterogeneous, with in some cases wider evidence of pain insensitivity. Narang et al. 7 reported a family in which three siblings, two girls (11 and 8 years) and a 5-year-old boy, all had a history of blistering followed by scarring on the nose and cheeks since early infancy. The lesions subsided with scarring. The children had been taken to various hospitals, investigated (no details given), biopsied and treated with multiple topical agents, but with no improvement. On examination, the children had postinflammatory hyperpigmentation and scarring on the nose and cheeks, with erythema reported on one occasion. The parents were not related. The father was absent and the mother's evident depression and doctor-seeking behaviour led to psychology referral. A diagnosis of Munchausen syndrome by proxy was 'confirmed when she confided that she had burnt her children's faces with hydrochloric acid, used as a toilet cleaner.' It seems unlikely that acid, applied to a presumably struggling child, would produce such discrete lesions, and one would expect significant ocular damage due to the proximity of the lesions to the eyes. In retrospect, the history and appearance are suggestive of MiTES. We recommend the following approach in future cases. The diagnosis is made clinically on the basis of history and clinical signs, and investigations should include routine haematology and biochemistry, serum uric acid levels and nerve conduction tests. If the diagnosis is uncertain, other possibilities can be explored by additional tests such as magnetic resonance imaging of the brain, lupus serology, porphyrins and skin biopsy with microbial culture.
The reports seem to confirm MiTES as a distinct phenotype that is genetically heterogeneous: an autosomal recessive type can be caused by biallelic PRDM12 polyalanine tract expansion, and possibly an autosomal dominant pattern by heterozygous mutations in SCN11A. MiTES may reflect a limited or early manifestation of CIP, but the appearance is consistent and recognizable. As more cases emerge, genotype-phenotype correlation may become apparent.
